Company: ABBV
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001551152-25-000040
Chunk: 62

Company: AbbVie Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 1
Chunk 62
---
 %$28,766 $26,772 7.4 %8.0 %

2025 Form 10-Q | 30

The following table details AbbVie’s worldwide net revenues: Three months endedJune 30,Percent changeSix months endedJune 30,Percent changeAt actual currency ratesAt constant currency ratesAt actual currency ratesAt constant currency rates(dollars in millions)2025202420252024ImmunologySkyriziUnited States$3,843 $2,340 64.3 %64.3 %$6,762 $3,996 69.2 %69.2 %International580 387 49.7 %47.2 %1,086 739 46.9 %49.6 %Total$4,423 $2,727 62.2 %61.8 %$7,848 $4,735 65.8 %66.2 %RinvoqUnited States$1,452 $1,017 42.7 %42.7 %$2,672 $1,742 53.3 %53.3 %International576 413 39.6 %37.5 %1,074 781 37.6 %40.1 %Total$2,028 $1,430 41.8 %41.2 %$3,746 $2,523 48.5 %49.3 %HumiraUnited States$802 $2,360 (66.0)%(66.0)%$1,546 $4,131 (62.6)%(62.6)%International378 454 (16.8)%(17.2)%755 953 (20.8)%(18.4)%Total$1,180 $2,814 (58.1)%(58.2)%$2,301 $5,084 (54.7)%(54.3)%NeuroscienceVraylarUnited States$898 $773 16.2 %16.2 %$1,661 $1,465 13.4 %13.4 %International2 1 72.8 %76.8 %4 3 41